Preclinical and clinical studies have demonstrated that anti-TWEAK monoclonal antibodies effectively reduce tissue infiltration of pathogenic macrophages in rheumatoid arthritis [56] and autoimmune encephalomyelitis [57], exhibiting therapeutic potential in managing irAEs. This evidence concerns the gene TNFSF12 and rheumatoid arthritis.